Overview

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects, good and/or bad, of MEK162 and imatinib on the patient and on Gastrointestinal Stromal Tumor (GIST). Funding Source - FDA OOPD, Array/Pfizer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Array BioPharma
University of Pittsburgh

Treatments:

Imatinib Mesylate